Clinical trials: Targeted Therapy
Neterton Syndrome
Successful Treatment of Netherton Syndrome With Combination of Secukinumab and Dupilumab
In this study, we describe our experience with secukinumab (IL-17A inhibitor) and dupilumab (IL-4/IL-13 inhibitor) treatment of a group of pediatric patients with severe Neterton syndrome.
- Trial name
- NCT07151508
- Testing
- Secukinumab was administered in a weight-adapted dosing regimen ? Dupilumab was administered at a dose dependent on the patient's weight and age
- Where
- Russia
- Volunteers
- 15 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Sarcoma
Advanced MR Imaging in Sarcoma Patients
We intend to investigate the clinical application of two emerging imaging modalities for which the technical capability is currently in place at Mayo Clinic.
- Trial name
- NCT02705391
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Mayo Clinic
HER2-positive Breast Cancer
Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy
Human epidermal growth factor receptor 2 (HER2) positive breast cancer is a molecular subtype with high malignancy and easy recurrence and metastasis.
- Trial name
- TaxDHER2 (NCT06711068)
- Where
- China
- Volunteers
- 8,077 people
- Sponsor
- Shu Wang
Malaria, Febrile Illness
Malaria Diagnostic Testing and Conditional Subsidies to Target ACTs in the Retail Sector: TESTsmART Aim 2 - Nigeria
Highly subsidized first-line antimalarials (artemisinin combination therapy or ACT) are available over the counter in the private retail sector in most malaria-endemic countries.
- Trial name
- NCT04428385
- Testing
- Testing incentive, Conditional artemisinin combination therapy subsidy
- Where
- Nigeria
- Volunteers
- 2,205 people
- Sponsor
- Duke University
CLL
Peptide-drug-conjugates for Personalized, Targeted Therapy of Chronic Lymphocytic Leukemia
Using phage libraries extensively pre-absorbed on a series of normal cell types, we will isolate phage specifically internalized by B-CLL cells from newly diagnosed and untreated CLL patients.
- Trial name
- NCT02828774
- Testing
- there will be no intervention.
- Volunteers
- 30 people
- Sponsor
- Assuta Medical Center
Allergy
Microbiota and Allergy
Food allergy derives from a dysregulation of oral tolerance mechanisms. Studies suggest a crucial role for gut microbiota in oral tolerance development.
- Trial name
- MATFA I (NCT04750980)
- Testing
- food allergy, respiratory allergy, healthy controls
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- Federico II University
Hematological Toxicity, Targeted Therapy
Real-world Study on the Management of Hematological Toxicities Associated With Targeted Therapies for Breast Cancer
This multicenter, real-world, observational study will retrospectively and prospectively collect real-world data related to the investigational drugs.
- Conditions
- Hematological Toxicity, Targeted Therapy, Breast Cancer
- Trial name
- NCT06503380
- Testing
- No intervenrion.
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Fudan University
Pediatric Solid Tumor
The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study
This research study is evaluating the use of specialized testing of solid tumors including sequencing. The process of performing these specialized tests is called tumor profiling.
- Trial name
- NCT02520713
- Testing
- Genetic testing and GAIN report
- Where
- 12 sites in United States
- Volunteers
- 825 people
- Sponsor
- Dana-Farber Cancer Institute
Nasopharyngeal Carcinoma
To Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC
This is a retrospective real-world study to evaluate the efficacy and feasibility of modified reduce-volume target IMRT in the treatment of patients with non-metastatic NPC
- Trial name
- NCT04387266
- Testing
- modified reduce-volume target IMRT
- Where
- China
- Volunteers
- 471 people
- Sponsor
- Fujian Cancer Hospital
Inflammatory Myofibroblastic Tumor
Study of Crizotinib in Children and Adolescents With Myofibroblastic Tumors
Targeted therapy based on target identification by genetic examinations is a promising direction in the treatment of patients with a complicated course of inflammatory myofibroblastic tumor.
- Trial name
- NCT03874273
- Testing
- Crizotinib
- Where
- Russia
- Volunteers
- 25 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Crohn Disease, Ulcerative Colitis
Clinical Study of Targeting CD7 CAR-T Cells in the Treatment of Autoimmune Diseases
A Clinical Study on the Safety and Effectiveness of Targeting CD7 Chimeric Antigen Receptor T Cells in the Treatment of Autoimmune Diseases
- Conditions
- Crohn Disease, Ulcerative Colitis, Dermatomyositis, Still Disease
- Trial name
- NCT05239702
- Testing
- CD7 CAR T-cells
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Zhejiang University
Neurocutaneous Syndromes, Neurofibromatosis Type 1 (NF1)
Precision Medicine for Neurocutaneous Syndromes in Western China
The goal of this observational study (retrospective multicenter cohort study) is to learn if precision medicine approaches-including genetic testing, targeted drugs, and coordinated care from multiple specialists-can improve…
- Conditions
- Neurocutaneous Syndromes, Neurofibromatosis Type 1 (NF1), Tuberous Sclerosis Complex (TSC), Sturge-Weber Syndrome (SWS)
- Trial name
- NCT07327164
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- West China Hospital
Malaria, Febrile Illness
Malaria Diagnostic Testing and Conditional Subsidies to Target ACTs in the Retail Sector: the TESTsmART Trial AIM 1
The TESTsmART Trial consists of two main aims. The overall goal of the two aims is to investigate the impact of malaria rapid diagnostic test (mRDT) subsidies and conditional artemisinin combination therapy (ACT) subsidies on the…
- Trial name
- TESTsmART (NCT03810014)
- Testing
- Conditional ACT subsidy, Arm 1 levels, Conditional ACT subsidy, Arm 2 levels, Conditional ACT subsidy, Arm 3 levels
- Where
- Kenya
- Volunteers
- 842 people
- Sponsor
- Duke University
Brain Tumor, Brain Tumor, Recurrent
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
SJELIOT is a phase 1 trial that aims to explore the combination of prexasertib with established DNA-damaging agents used in medulloblastoma to evaluate tolerance and pharmacokinetics in recurrent or refractory disease.
- Conditions
- Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Refractory, Brain Tumor, Pediatric
- Trial name
- NCT04023669
- Testing
- Prexasertib, Cyclophosphamide, Gemcitabine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- St. Jude Children's Research Hospital
Treatment Outcome
Lubinus SPII Hip Stem Target Trial Emulation
The research questions this study aims to answer are as follows: Primary research question: "Do primary total hip arthroplasties for patients with OA, hip fracture or osteonecrosis with the 150mm Lubinus SPII hip stem have better…
- Trial name
- LARGE (NCT06367829)
- Testing
- Lubinus SPII hip stem 130mm, Lubinus SPII hip stem 150mm
- Where
- Netherlands
- Volunteers
- 110,000 people
- Sponsor
- JointResearch
Sickle Cell Anemia
Risk-based Therapy for Sickle Cell Anemia: A Feasibility Study
Sickle cell anemia (SCA) patients experience organ damage that begins at an early age and results in significant morbidity and early mortality.
- Trial name
- NCT02090296
- Testing
- Hydroxyurea
- Where
- United States
- Sponsor
- Children's National Research Institute
Impaired Renal Function
Computer Prescribing System and Impaired Renal Function
To evaluate the quality of orders for target drugs in old patients with impaired renal function, hospitalized or living in long stay units, and to improve these practices by means of a counselling system coupled to a computer…
- Trial name
- Ordoclic-IR (NCT00784381)
- Testing
- computer-assisted counselling about target drugs
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Metastatic Solid Tumors (Any Localization)
Molecular Screening for Cancer Treatment Optimization
The primary objective of the study is to use high throughput molecular analysis (CGH Array and sequencing) to treat patients with metastatic cancer with targeted therapeutics in order to improve the progression free survival…
- Trial name
- MOSCATO 02 (NCT01566019)
- Testing
- Tumoral biopsy
- Where
- France
- Volunteers
- 2,150 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
B Cell Malignancies
CD19/79b Bi-specific CAR-T Cell Therapy
The purpose of this study is to assess the feasibility, safety and efficacy of CD19/79b bi-specific CAR-T cell therapy in patients with CD19 and/or CD79b positive B cell malignancies.
- Trial name
- NCT05436509
- Testing
- bi-4SCAR CD19/79b T cells
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Recurrent UTIs, Catheter-Related Infections
Novel Probiotic Treatment for Prevention of Recurrent UTIs in Children
Background: Urinary tract infections (UTIs) are a common and costly cause of doctor visits for children. Frequent UTIs trigger kidney damage that leads to serious diseases like high blood pressure, pregnancy complications, and…
- Trial name
- Nissle 1917 (NCT01696227)
- Testing
- Nissle 1917
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Nationwide Children's Hospital